All In MedTech

FDA Clearance Tracker · P970043-S007

LADAR VISION EXCIMER LASER SYSTEM (HYPEROPIA)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Sep 22, 2000 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Sep 22, 2000

Approved

Time to decision

385 days

Received Sep 3, 1999. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P970043-S007
Device name
LADAR VISION EXCIMER LASER SYSTEM (HYPEROPIA)
Applicant location
Fort Worth, TX
Received
Sep 3, 1999
Decided
Sep 22, 2000
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Change Design/Components/Specifications/Material
Expedited review
Yes, flagged as expedited in FDA's record.
Original approval
P970043

Device type

Device class
Class III
Specialty
Ophthalmology

Every decision under product code LZS

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE LADARVISION(R) EXCIMER LASER SYSTEM. THE DEVICE IS INDICATED FOR LASER IN-SITU KERATOMILEUSIS (LASIK) TREATMENTS: 1) FOR THE REDUCTION OR ELIMINATINO OF REFRACTIVE ERROR OF LESS THAN OR EQUAL TO +6.00D OF SPHERE AND -6.00D OF CYLINDER AT THE SPECTACLE PLANE (HYPEROPIA WITH OR WITHOUT ASTIGMATISM AND MIXED ASTIGMATISM); 1) IN SUBJECTS WITH DOCUMENTED STABILITY OF REFRACTION FOR THE PRIOR 12 MONTHS, AS DEMONSTRATED BY A CHANGE OF LESS THAN OR EQUAL TO 0.50D FOR CORRECTIONS UP TO +6.00D SE; AND, 3) IN SUBJECTS WHO ARE 21 YEARS OF AGE OR OLDER.

Source documents

Other decisions for Alcon Laboratories

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.